Celecoxib pre-treatment in human colorectal adenocarcinoma patients is associated with gene expression alterations suggestive of diminished cellular proliferation

Abstract Cancer cells treated with the cyclooxygenase-2 inhibitor celecoxib show growth inhibition and induced apoptosis. This study was conducted to determine if the same processes are relevant to celecoxib’s effects on human colorectal adenocarcinomas treated in vivo . A cohort of 23 patients with...

Full description

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) 2008-08, Vol.44 (12), p.1754-1760
Main Authors: Auman, James Todd, Church, Robert, Lee, Soo-Youn, Watson, Mark A, Fleshman, James W, Mcleod, Howard L
Format: Article
Language:English
Subjects:
Adenocarcinoma - drug therapy
Adenocarcinoma - genetics
Adenocarcinoma - surgery
Biological and medical sciences
cDNA microarrays
Celecoxib
Cell Proliferation - drug effects
Colorectal neoplasms
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - genetics
Colorectal Neoplasms - surgery
Cyclooxygenase 2 inhibitors
Cyclooxygenase 2 Inhibitors - therapeutic use
Female
Gene Expression - drug effects
Gene Expression Profiling
Hematology, Oncology and Palliative Medicine
Humans
Male
Medical sciences
Pharmacology. Drug treatments
Preoperative Care
Pyrazoles - therapeutic use
Sulfonamides - therapeutic use
Treatment Outcome
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Cancer cells treated with the cyclooxygenase-2 inhibitor celecoxib show growth inhibition and induced apoptosis. This study was conducted to determine if the same processes are relevant to celecoxib’s effects on human colorectal adenocarcinomas treated in vivo . A cohort of 23 patients with primary colorectal adenocarcinomas was randomised to receive a 7-d course of celecoxib (400 mg b.i.d.) or no drug prior to surgical resection. Gene expression profiling was performed on resected adenocarcinomas from the cohort of patients. Using fold change (>1.5) and p -value (
ISSN:0959-8049
1879-0852
DOI:10.1016/j.ejca.2008.05.010